Program
apadamtase alfa
Also written as “TAK-755”, “SHP655” and “Recombinant ADAMTS13”.
Its studies are mostly in Purpura, Thrombotic Thrombocytopenic · Ischemic Stroke · Anemia, Sickle Cell, led by Takeda.
Furthest: phase 3, since Oct 5, 20177 company-led studies, 2 open or runningNext primary completion: Mar 16, 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Takeda | 72 open or running | phase 3since Oct 5, 2017 | Aug 12, 2014 | Mar 16, 2027phase 3 · NCT04683003 |
Also a collaborator on its studies: Takeda Development Center Americas.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 12, 2014First study: phase 1 study in Hereditary Thrombotic Thrombocytopenic Purpura (TTP)First studyNCT02216084 · 16 enrolled · United States, Austria, Germany and more
- Oct 5, 2017Phase 3 study in Purpura, Thrombotic ThrombocytopenicNCT03393975 · 52 enrolled · United States, Austria, France and more
- Apr 5, 2019Phase 2 study in Purpura, Thrombotic ThrombocytopenicNCT03922308 · 28 enrolled · United States, Canada, France and more
- Jun 14, 2019Phase 1 study in Anemia, Sickle CellNCT03997760 · 19 enrolled · United States
- Dec 10, 2020Phase 3 study in Purpura, Thrombotic ThrombocytopenicNCT04683003 · 77 enrolled · United States, Austria, China and more
- Jan 24, 2023Phase 2 study in Purpura, Thrombotic ThrombocytopenicNCT05714969 · 29 enrolled · United States, Austria, Greece and more
- Jan 30, 2026Phase 2 study in Ischemic StrokeNCT07392450 · 222 planned · United States, Belgium, Brazil and more
Ahead
- Mar 16, 2027Primary completion: phase 3 study in Purpura, Thrombotic ThrombocytopenicNCT04683003
- Dec 6, 2027Primary completion: phase 2 study in Ischemic StrokeNCT07392450
TargetBeta
ADAMTS13 →read by rule
“A recombinant human form of a disintegrin and metalloproteinase with thrombospondin motifs 13 (ADAMTS13) that may be used as a replacement therapy for ADAMTS13 with indirect anti-thrombotic and anti-thrombocytopenic activities”NCIt, by rule
“A disintegrin and metalloproteinase with thrombospondin motifs 13 exogenous protein”ChEMBL 37, by rule
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07392450Ischemic Stroke · United States, Belgium, Brazil and more | 2 | Recruiting | Dec 6, 2027 | 222 |
| NCT05714969Purpura, Thrombotic Thrombocytopenic · United States, Austria, Greece and more | 2 | Completed | Apr 16, 2026 | 29 |
| NCT04683003Purpura, Thrombotic Thrombocytopenic · United States, Austria, China and more | 3 | Active, not recruiting | Mar 16, 2027 | 77 |
| NCT03997760Anemia, Sickle Cell · United States | 1 | Completed | Oct 26, 2022 | 19 |
| NCT03922308Purpura, Thrombotic Thrombocytopenic · United States, Canada, France and more | 2 | Completed | Aug 5, 2021 | 28 |
| NCT03393975Purpura, Thrombotic Thrombocytopenic · United States, Austria, France and more | 3 | Completed | Dec 28, 2023 | 52 |
| NCT02216084Hereditary Thrombotic Thrombocytopenic Purpura (TTP) · United States, Austria, Germany and more | 1 | Completed | Feb 22, 2016 | 16 |
How it is read
Names in the registry
- “TAK-755”, 5 entries
- “SHP655”, 1 entry
- “Recombinant ADAMTS13”, 1 entry
Conditions, from the studies’ own filings
- Purpura, Thrombotic Thrombocytopenic, 5 studies
- Ischemic Stroke, 1 study
- Anemia, Sickle Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.